公司资料
Vaxart 股价、新闻与催化剂
- 股票代码:
- VXRT
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.49 USD (-9.11%)
收盘价
最后更新: 2026年8月17日
—
市值
股价为何变动
As of Aug 17, 2026, VXRT closed down 9.11% at $0.4940. No new same-company headline was identified in the current news window.
公司概览
Oral Vaccine Platform
Vaxart is a clinical-stage biotechnology company developing recombinant vaccines delivered as pills. Its platform is designed to eliminate injections and enable products that can be stored and shipped without refrigeration.
Mucosal Immunization Approach
The delivery technology combines an adenoviral vector with a TLR3 agonist to stimulate immune responses at mucosal surfaces. Vaxart aims to create oral alternatives to existing injectable vaccines and vaccines for indications without established products.
COVID-19 Program
The lead Phase 2b program compares Vaxart's oral COVID-19 vaccine with an approved mRNA vaccine. A 400-participant sentinel cohort assessed safety before analysis of the approximately 5,000-participant main cohort.
Broader Vaccine Pipeline
Additional development programs target norovirus and influenza, while a therapeutic HPV vaccine represents the platform's first immuno-oncology application.
未来催化剂
- Topline efficacy and safety results from the complete Phase 2b COVID-19 study in the first half of 2027.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。